The pathways enrichment analysis indicated TMSB10 was positively associated with IL6/JAK/STAT3 signaling pathway (Figure S4), and we also found TMSB10 was positively associated with IL-6 in patients with primary/recurrent glioma (Figures S5A-H, grade III: r=0.46, P<0.001, grade IV: r=0.317, P=0.003). Here, IL6 is linked to glioma.